Pálffy R, Gardlík R, Hodosy J, Behuliak M, Resko P, Radvánský J, Celec P
BiomeD Research and Publishing Group, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic.
Gene Ther. 2006 Jan;13(2):101-5. doi: 10.1038/sj.gt.3302635.
Recent advances in gene therapy can be attributed to improvements of gene delivery vectors. New viral and nonviral transport vehicles that considerably increase the efficiency of transfection have been prepared. However, these vectors still have many disadvantages that are difficult to overcome, thus, a new approach is needed. The approach of bacterial delivery could in the future be important for gene therapy applications. In this article we try to summarize the most important modifications that are used for the preparation of applied strains, difficulties that are related with bacterial gene delivery and the current use of bactofection in animal experiments and clinical trials. Important differences to the alternative gene therapy (AGT) are discussed. AGT resembles bacteria-mediated protein delivery, as the therapeutical proteins are produced not by host cells but by the bacteria in situ and the expression can be regulated exogenously. Although the procedure of bacterial gene delivery is far from being definitely solved, bactofection remains a promising technique for transfection in human gene therapy.
基因治疗的最新进展可归因于基因传递载体的改进。已经制备出了能显著提高转染效率的新型病毒和非病毒运输载体。然而，这些载体仍存在许多难以克服的缺点，因此，需要一种新方法。细菌递送方法未来可能在基因治疗应用中具有重要意义。在本文中，我们试图总结用于制备应用菌株的最重要修饰、与细菌基因递送相关的困难以及细菌转染在动物实验和临床试验中的当前应用。还讨论了与替代基因治疗（AGT）的重要差异。AGT类似于细菌介导的蛋白质递送，因为治疗性蛋白质不是由宿主细胞产生，而是由细菌在原位产生，并且表达可以外源调节。尽管细菌基因递送过程远未得到彻底解决，但细菌转染仍是人类基因治疗中有前景的转染技术。
